Blood tests could fine-tune IBD treatment, saving money and improving lives
NCT ID NCT02508012
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether regularly measuring levels of anti-TNF drugs and antibodies in the blood can help doctors better manage inflammatory bowel disease (Crohn's and ulcerative colitis). 260 patients were split into two groups: one where doctors used these test results to adjust treatment, and one where they did not. The goal was to see if this monitoring approach improves quality of life and is cost-effective over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-TNF drugs (e.g., infliximab, adalimumab)
What this could lead to
If successful, this approach could help doctors adjust treatment more precisely, improving disease control and reducing costs for IBD patients.
What could go wrong
This is a completed study, not a new treatment. The monitoring strategy may not significantly improve outcomes or be cost-effective in all settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University hospital
Montpellier, 34295, France